期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 72, 期 1, 页码 3-6出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-202361
关键词
-
类别
资金
- Abbott
- Astra-Zeneca
- BMS
- Celgene
- Glaxo
- Janssen
- Lilly
- Medimmune
- MSD
- Novartis-Sandoz
- Novo-Nordisk
- Pfizer
- Roche
- Teva
- UCB
In this viewpoint, we summarise three different lines of evidence suggesting that current biological therapies directed at different molecules or cells have similar efficacy in rheumatoid arthritis and target similar populations of patients; therefore, distinct biological effects of targeted therapies may not account for differences in response. Moreover, currently available individual biomarkers or multiple biomarker sets do not provide information beyond that conveyed by clinical disease activity. Smart and novel research designs will have to be developed to find pertinent biomarkers. Until then, the focus of clinicians may have to solely rest on clinical disease activity assessment and targeting remission or low disease activity rapidly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据